<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00292383</url>
  </required_header>
  <id_info>
    <org_study_id>V-PASS V.1.2.</org_study_id>
    <nct_id>NCT00292383</nct_id>
  </id_info>
  <brief_title>Ventricular Pacing Site Selection (V-PASS)</brief_title>
  <official_title>A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic BRC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitatron GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic BRC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is a relationship between ventricular
      lead position and the incidence of heart failure and atrial fibrillation in patients with
      indication for permanent pacemaker stimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AV-Block of higher degree is the primary indication for pacing therapy for about 20% of
      pacemaker patients. Pacing systems with only ventricular stimulation (VVI and VDD) have a
      fraction of about 40% of all pacemakers in Germany. About 50% of the implanted pacemakers in
      Germany are dual-chamber pacemakers and one half of them is used for treatment of AV blocks.

      Picture 1: Fractions of pacing indications in Germany Picture 2: Fractions of used pacing
      modes in Germany /1/

      A lot of studies proved in the past that the pacing site influenced the development of
      hemodynamics, heart failure (HF) and atrial fibrillation (AF). Unfortunately, the results are
      not commonly applicable or statistically assured. Due to this, further examinations are
      required in order to get explicit statements regarding application of alternative, nonapical
      ventricular lead positioning.

        1. Pilotphase It shall be determined whether a randomized positioning of ventricular leads
           at 2 defined positions (either Group A: Positioning at right ventricular apex or Group
           B:. Positioning at right ventricular high septum) is feasible. Included patients will
           already by examined and followed according to protocol. After having proved feasibility
           of randomized positioning, the data of these patients shall be used for evaluation of
           the V-PASS study.

        2. Study Phase It shall be evaluated how far 2 defined different ventricular lead positions
           for permanent pacemaker therapy can influence the combined study endpoint mortality and
           clinically relevant symptoms of heart failure. Further more the development of
           hemodynamics and the incidence of atrial fibrillation shall be studied.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <completion_date>December 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of patients in which the ventricular lead position could be positioned successfully according randomization</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Typical values re operation procedure in both groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation time, x-ray time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative measurements (amplitudes, thresholds)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>broad QRS-complexes in both groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of therapy, complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrical specific values in both groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy consumption, lead impedance</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythmologic characteristics in both groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of VESs</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>episodes of ventricular tachycardia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of atrial and ventricular stimulation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP-levels in both groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of co-morbidities in both groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation, AF burden &gt;1%</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure &gt; NYHA II</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations in both groups due to</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhythm disorders</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrioventricular Block</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with an expected ventricular stimulation rate of &gt;60% in planned pacing therapy.
        This will be the following pacing indications

          -  Symptomatic first-degree AV block, PQ time &gt;250ms

          -  Second-degree Av block with permanent 2:1 conduction

          -  Permanent third-degree AV block

          -  Paroxysmal first-degree to third-degree Av block, with an anticipated rate of
             ventricular stimulation &gt;60%

          -  Symptomatic bradyarrhythmia absoluta with permanent atrial fibrillation, with an
             anticipated rate of ventricular stimulation &gt;60%

        Exclusion Criteria:

          -  heart failure acc. NYHA III or IV

          -  Intra-atrial conduction delay (P-wave &gt; 150ms)

          -  Myocardial infarction less then 6 months before pacemaker implant

          -  hypertrophic obstructive cardiomyopathy

          -  Cardiogenic shock

          -  pregnancy

          -  Lactation period

          -  Patients under 18 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochem F. Stockinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Bad Krozingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias E Reimers, Dipl. Documentalist</last_name>
    <phone>0049021152930</phone>
    <phone_ext>422</phone_ext>
    <email>Matthias.reimers@vitatron.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steffen Gazarek, Dr., Engineer</last_name>
    <phone>004901729135662</phone>
    <email>steffen.gazarek@vitatron.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen, Elektrophysiologie</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>D-79189</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochem Stockinger, MD</last_name>
      <phone>0049 07633402</phone>
      <phone_ext>248</phone_ext>
      <email>JFStockinger@gmx.de</email>
    </contact>
    <investigator>
      <last_name>Jochem Stockinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Blum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Innere Medizin III</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Bauer, MD</last_name>
      <phone>++49 0622563</phone>
      <phone_ext>8672</phone_ext>
      <email>Alexander.Bauer@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Alexander Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oberschwaben Klinik GmbH, Krankenhaus Wangen, Innere Med.</name>
      <address>
        <city>Wangen</city>
        <zip>D-88239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jörg Maurus, MD</last_name>
      <phone>0049 00752296</phone>
      <phone_ext>1311</phone_ext>
    </contact>
    <investigator>
      <last_name>Jörg Maurus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Fachgruppe Herzschrittmacher. Bericht des Deutschen Herzschrittmacher Registers 2003 http://www.pacemaker-register.de/pdf/zentralregister_herzschrittmacher_bericht03.pdf</citation>
  </reference>
  <reference>
    <citation>DÄNISCHES HERZSCHRITTMACHERREGISTER http://www.pacemaker.dk</citation>
  </reference>
  <reference>
    <citation>SCHWEIZER HERZSCHRITTMACHERREGISTER http://www.pacemaker.ch</citation>
  </reference>
  <reference>
    <citation>Lemke B., Nowak B. Pfeiffer D. Leitlinien zur Herzschritmachertherapie. Deutsche Gesellschaft für Kardiologie 2005. http://www.dgk.org/leitlinien/LLHerzschrittmacher.pdf</citation>
  </reference>
  <reference>
    <citation>Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008 May 27;51(21):e1-62. doi: 10.1016/j.jacc.2008.02.032. Erratum in: J Am Coll Cardiol. 2009 Apr 21;53(16):1473. J Am Coll Cardiol. 2009 Jan 6;53(1):147.</citation>
    <PMID>18498951</PMID>
  </reference>
  <reference>
    <citation>Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, Marinchak RA, Flaker G, Schron E, Orav EJ, Hellkamp AS, Greer S, McAnulty J, Ellenbogen K, Ehlert F, Freedman RA, Estes NA 3rd, Greenspon A, Goldman L; Mode Selection Trial in Sinus-Node Dysfunction. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002 Jun 13;346(24):1854-62.</citation>
    <PMID>12063369</PMID>
  </reference>
  <reference>
    <citation>Fröhlig G, Schwaab B, Kindermann M. Selective site pacing: the right ventricular approach. Pacing Clin Electrophysiol. 2004 Jun;27(6 Pt 2):855-61. Review.</citation>
    <PMID>15189516</PMID>
  </reference>
  <reference>
    <citation>Koglek W, Kranig W, Kowalski M, Kronski D, Brandl J, Oberbichler A, Suntinger A, Wutte M, Grimm G, Grove R, Lüdorff G. [A simple method for AV-delay determination in dual chamber pacemakers]. Herzschrittmacherther Elektrophysiol. 2000 Dec;11(4):244-53. doi: 10.1007/s003990070023. German.</citation>
    <PMID>27515355</PMID>
  </reference>
  <reference>
    <citation>Giudici MC, Thornburg GA, Buck DL, Coyne EP, Walton MC, Paul DL, Sutton J. Comparison of right ventricular outflow tract and apical lead permanent pacing on cardiac output. Am J Cardiol. 1997 Jan 15;79(2):209-12.</citation>
    <PMID>9193029</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2006</study_first_submitted>
  <study_first_submitted_qc>February 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2006</study_first_posted>
  <last_update_submitted>August 1, 2011</last_update_submitted>
  <last_update_submitted_qc>August 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2011</last_update_posted>
  <keyword>Cardiac Pacing, artificial</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Pacemaker leads</keyword>
  <keyword>Lead position</keyword>
  <keyword>Higher degree AV-Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

